Pancreatic cancer
Conditions
Interventions
RPC cohort (Surgery ? Adjuvant therapy + nimotuzumab):NA
BRPC cohort (Neoadjuvant chemotherapy+ nimotuzumab ? Surgery ? adjuvant chemotherapy ± nimotuzumab):NA
LAPC/mPC cohort (nimotuzumab ± standard therapy):NA
Sponsors
Anhui Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 95 Years
Inclusion criteria
Inclusion criteria: 1)Age = 18 years old, gender is not limited; 2)Patients diagnosed with pancreatic ductal adenocarcinoma (PDAC) by histopathology or cytology; 3)All patients voluntarily received nintedanib ± standard of care (SOC); 4)According to the RECIST 1.1 evaluation criteria, there are measurable lesions; 5)Voluntarily sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1)Other primary malignant tumors other than pancreatic cancer (except cured skin basal cell carcinoma and cervical carcinoma in situ); 2)Previously received EGFR targeted therapy; 3)Other reasons that the researchers judged were not suitable for participating in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival (OS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival;Disease-free survival;Objective Response Rate;Disease Control Rate;Time to progression;Conversion resection rate;R0 resection rate;Adverse event; | — |
Countries
CHINA
Contacts
Public ContactHE YIFU
Anhui Cancer Hospital
Outcome results
None listed